Logo image of PEAR

PEAR THERAPEUTICS INC (PEAR) Stock Fundamental Analysis

NASDAQ:PEAR - Nasdaq - US7047231052 - Common Stock - Currency: USD

0.0292  -0.02 (-38.91%)

After market: 0.0287 0 (-1.71%)

Fundamental Rating

3

Overall PEAR gets a fundamental rating of 3 out of 10. We evaluated PEAR against 39 industry peers in the Health Care Technology industry. PEAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PEAR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PEAR has reported negative net income.
In the past year PEAR has reported a negative cash flow from operations.
PEAR Yearly Net Income VS EBIT VS OCF VS FCFPEAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

PEAR has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PEAR Yearly ROA, ROE, ROICPEAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 41.75%, PEAR is doing worse than 64.44% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for PEAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PEAR Yearly Profit, Operating, Gross MarginsPEAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

PEAR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PEAR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for PEAR is higher compared to a year ago.
PEAR Yearly Shares OutstandingPEAR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 50M 100M
PEAR Yearly Total Debt VS Total AssetsPEAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M

2.2 Solvency

PEAR has an Altman-Z score of -8.36. This is a bad value and indicates that PEAR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PEAR (-8.36) is worse than 75.56% of its industry peers.
PEAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.36
ROIC/WACCN/A
WACC10.97%
PEAR Yearly LT Debt VS Equity VS FCFPEAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 50M -50M -100M

2.3 Liquidity

PEAR has a Current Ratio of 1.48. This is a normal value and indicates that PEAR is financially healthy and should not expect problems in meeting its short term obligations.
PEAR has a Current ratio (1.48) which is in line with its industry peers.
A Quick Ratio of 1.48 indicates that PEAR should not have too much problems paying its short term obligations.
PEAR has a Quick ratio (1.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
PEAR Yearly Current Assets VS Current LiabilitesPEAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.78% over the past year.
Looking at the last year, PEAR shows a very strong growth in Revenue. The Revenue has grown by 201.66%.
EPS 1Y (TTM)11.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)201.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.04%

3.2 Future

PEAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.42% yearly.
PEAR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 81.05% yearly.
EPS Next Y10%
EPS Next 2Y28.84%
EPS Next 3Y16.96%
EPS Next 5Y23.42%
Revenue Next Year119.68%
Revenue Next 2Y113.93%
Revenue Next 3Y110.5%
Revenue Next 5Y81.05%

3.3 Evolution

PEAR Yearly Revenue VS EstimatesPEAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PEAR Yearly EPS VS EstimatesPEAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PEAR. In the last year negative earnings were reported.
Also next year PEAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PEAR Price Earnings VS Forward Price EarningsPEAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PEAR Per share dataPEAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEAR's earnings are expected to grow with 16.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.84%
EPS Next 3Y16.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PEAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PEAR THERAPEUTICS INC

NASDAQ:PEAR (4/18/2023, 8:27:07 PM)

After market: 0.0287 0 (-1.71%)

0.0292

-0.02 (-38.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-27 2023-03-27
Earnings (Next)05-15 2023-05-15
Inst Owners0%
Inst Owner Change0%
Ins Owners10.65%
Ins Owner Change0%
Market Cap4.17M
Analysts76.67
Price Target5.44 (18530.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.45%
Min EPS beat(2)-0.45%
Max EPS beat(2)-0.45%
EPS beat(4)1
Avg EPS beat(4)35.19%
Min EPS beat(4)-9.93%
Max EPS beat(4)115.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-20.45%
Min Revenue beat(2)-41.44%
Max Revenue beat(2)0.54%
Revenue beat(4)2
Avg Revenue beat(4)-13.07%
Min Revenue beat(4)-41.44%
Max Revenue beat(4)12.34%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)39.13%
PT rev (3m)3.7%
EPS NQ rev (1m)3.78%
EPS NQ rev (3m)3.78%
EPS NY rev (1m)13.96%
EPS NY rev (3m)6.19%
Revenue NQ rev (1m)-12.99%
Revenue NQ rev (3m)-12.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.09
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.75%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z -8.36
F-Score3
WACC10.97%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next Y10%
EPS Next 2Y28.84%
EPS Next 3Y16.96%
EPS Next 5Y23.42%
Revenue 1Y (TTM)201.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.04%
Revenue Next Year119.68%
Revenue Next 2Y113.93%
Revenue Next 3Y110.5%
Revenue Next 5Y81.05%
EBIT growth 1Y-5.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.45%
OCF growth 3YN/A
OCF growth 5YN/A